Analyst Ratings For Dechra Pharmaceuticals plc (LON:DPH)
Today, FinnCap reiterated its Under Review rating on Dechra Pharmaceuticals plc (LON:DPH).
There are 3 hold ratings, 3 buy ratings on the stock.
The current consensus rating on Dechra Pharmaceuticals plc (LON:DPH) is Buy (Score: 2.50) with a consensus target price of GBX 1,337.43 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Under Review.
- 1/26/2017-Panmure Gordon Reiterated Rating of Under Review.
- 1/17/2017-Numis Securities Ltd Reiterated Rating of Add.
- 10/21/2016-Stifel Nicolaus Reiterated Rating of Hold.
About Dechra Pharmaceuticals plc (LON:DPH)
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Genera and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine and Food producing Animal Products. It includes third party manufacturing and other non-core activities sales. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal and Equine Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos and Vetoryl.
Recent Trading Activity for Dechra Pharmaceuticals plc (LON:DPH)
Shares of Dechra Pharmaceuticals plc closed the previous trading session at 1,538.00 0.00 0.00% with 129,187 shares trading hands.
